Management of Parkinson's disease: A review of current and new therapies

Canadian Journal of Neurological Sciences

Volumn 26, Issue 2, 1999, Pages 89-103

  Mendis, Tilak ^a   Suchowersky, Oksana ^b   Lang, Anthony ^b   Gauthier, Serge ^b  

^a Elisabeth Bruyere Research Institute   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; BENSERAZIDE PLUS LEVODOPA; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DESIPRAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; EDEPRYL; IMIPRAMINE; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; OLANZAPINE; ONDANSETRON; PERGOLIDE; PRAMIPEXOLE; QUETIAPINE; REMACEMIDE; RISPERIDONE; ROPINIROLE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TOCOPHEROL; TOLCAPONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ANXIETY NEUROSIS; COGNITION; DEPRESSION; DIARRHEA; DRUG INDICATION; DYSKINESIA; ELECTROCONVULSIVE THERAPY; EXERCISE; HUMAN; NAUSEA; ORTHOSTATIC HYPERTENSION; PALLIDOTOMY; PARKINSON DISEASE; PHYSIOTHERAPY; PRIORITY JOURNAL; RETROPERITONEAL FIBROSIS; REVIEW; THALAMOTOMY; TREATMENT PLANNING; VOMITING;

ANTIPARKINSON AGENTS; ANXIETY; AUTONOMIC NERVOUS SYSTEM DISEASES; DEPRESSION; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PSYCHOSES, SUBSTANCE-INDUCED;

EID: 0032942169     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (186)

1. Charcot JM. Lectures on the diseases of the nervous system. London: The New Sydenham Society, 1877.
2. Barbeau A. The pathogenesis of Parkinson's disease: a new hypothesis. Can Med Assoc J 1962; 87: 802-807.
3. Comelia C, Tanner CM. Anticholinergic drugs in the treatment of Parkinson's disease. In: Koller WC, Paulson G, eds. Therapy of Parkinson's disease. New York: Marcel Dekker, 1990; 123-160.
4. Schwab RS, England ECJ, Poskanzer DC, Young KR. Amantadine in the treatment of Parkinson's disease. JAMA 1969; 208: 1168-1170.
5. Parkes JD, Zilkha KH, Marsden D, Baxter RC, Knill-Jones RP. Amantadine dosage in treatment of Parkinson's disease. Lancet 1970;1: 1130-1133.
6. Walker JE, Albers JW, Tourtelotte WW, Henderson WG, Potvin AR, Smith A. A qualitative and quantitive evaluation of amantadine in the treatment of Parkinson's disease. J Chron Dis 1972;25: 149-182.
7. Parkes JD, Calver DM, Zilkha KH, Knill-Jones RP. Controlled trial of amantadine hydrochloride in Parkinson's disease. Lancet 1970; 1: 259-262.
8. Grelak RP, Clark R, Stump JM, Vernier VG. Amantadine-dopamine interaction: possible mode of action in parkinsonism. Science 1970; 169: 203-204.
9. Von Voightlander PF, Moore KE. Dopamine: release from the brain in vivo by amantadine. Science 1971; 174: 408-409.
10. Merrick EM, Schmitt PP. A controlled study of the clinical effects of amantadine in hydrochloride (Symmetrel). Cur Thera Res 1973; 15: 552-558.
11. Farnebo LO, Fuxe K, Goldstein M, Hamberger B, Ungerstedt U. Dopamine an noradrenaline releasing action of amantadine in the central and peripheral nervous system: a possible mode of action in Parkinson's disease. Eur J Pharm 1971; 16: 27-38.
12. Bormann J. Memantine is a potent blocker of NMDA receptor channels. Eur J Pharm 1989; 166: 591-592.
13. Uitti RJ, Rajput AH, Ahlskog JE, et al. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 1996; 46: 1551-1556.
14. Koller WC, Silver DE, Lieberman A. An algorithim for the management of Parkinson's disease. Neurology 1994; 33 (12 Suppl 10): S1-S52.
15. Hoehn M. Parkinson's disease: progression and mortality. Adv Neurol 1986; 45: 457-461.
16. Birkmayer W, Hornykiewicz O. Der L-3,4-diphenylalanin(=DOPA) Effekt bei der Parkinson-Akinese. Wien Klin Wochenschr 1961; 73: 787-788.
17. Cotzias GC, Papvasilou PS. Therapeutic studies of parkinsonian patients: long term effects of D,L- and L-Dopa. Presented at the Second International Congress of Neuro-ophthalmology; Sept 19, 1967; Montreal, Canada.
18. Yen KC, August TF, Bush DF, et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 1989; 39: 25-38.
19. Gauthier S, Rajput A, Suchowersky O, et al. Canadian multicenter study of initiating Sinemet CR treatment in patients with idiopathic Parkinson's disease. 11th International Symposium on Parkinson's disease 1994; Rome,March,(Abstract).
20. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1977; 1: 349.
21. Poewe WH, Lees AJ, Stern GM. Low dose L-dopa therapy in Parkinson's disease: A 6-year follow-up study. Neurology 1986; 36: 1528-1530.
22. Muenter MD, Sharpless NS, Tyce SM, Darley FL. Patterns of dystonia ("I-D-I" and "D-I-D") in response to L-dopa therapy for Parkinson's disease. Mayo Clin Proc 1977; 52: 163-174.
23. Lhermitte F, Agid Y, Signoret JL. Onset and end of dose levodopa-induced dyskinesias. Possible treatment by increasing the daily doses of levodopa. Arch Neurol 1978; 35: 261-263.
24. Chase TN, Engber TM, Mouradian MM. Palliative and prophylactic benefits of continously administered dopaminomimetics in Parkinson's disease. Neurology 1994; 44: S15-S18.
25. Koller WC, Pahwa R. Treating motor fluctuations with controlled release levodopa preparations. Neurology 1994; 44: S23-S28.
26. Block G, Liss C, Reines S, et al. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. Eur J Neurol 1997; 37: 23-27.
27. Caplideo R. Implications of the 5-year CR FIRST trial. Neurology 50 (Suppl 6) June 1998 S11-S14.
28. Juncos JL, Mouradian MM, Fabbrini G, Chase TN. Levodopa infusion therapy. In: Koller WC, Paulson G, eds. Therapy of Parkinson's disease. New York: Marcel Dekker Inc. 1990.
29. Kurlan R, Nutt JG, Woodward WR, et al. Duodenal and gastric delivery of levodopa in parkinsonism. Ann Neurol 1988; 23: 589-595.
30. Sage JI, Trooskin S, Sonsalla PK, Heikkila R, Duvoisin RC. Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol 1988; 24: 87-89.
31. Cohen G. Oxidative stress in the nervous system. In: Sies H; emergency department. Oxidative stress. New York: Academic Press; 1985: 383-402.
32. Adams JD, Odunze N. Oxygen Free Radicals and Parkinson's disease. Free Radical Biology and Medicine, 1991; 10: 161-169.
33. Agid Y. Levodopa: is toxicity a myth? Neurology 1998 Apr; 50(4): 858-63.
34. Rajput AH, Uitti RJ, Rajput AH, Offord KP. Timely Levodopa (LD) Administration prolongs survival in Parkinson's disease. Parkinsonism and Related Disorders 1997; 3(3): 159-165.
35. Wolters EC, Tissingh G, Bergmans PLM, Kuiper MA. Dopamine agonists in Parkinson's disease. Neurology 1995; 43: S28-S34.
36. Pezzoli G, Martignoni E, Pacchetti C, et al. A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease. Neurology 1995; 43: S22-S27.
37. Demonet JF, Rostin M, Dueymes JM, lovalalen A, Montastruc JL, Rascol A. Retroperitoneal fibrosis and treatment of Parkinson's disease with high doses of bromocriptine. Clin Neuropharmacol 1986; 9: 200-201.
38. Jimenez-Jimemez FJ, Lopez-Alvarez J, Sanchez-Chapado M, et al. Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide. Clin Neuropharmacol 1995; 18: 277-279.
39. Adler C, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. Neurology 1997; 49: 393-399.
40. Brooks DJ, Torjanski N, Burn DJ. Ropinirole in the symptomatic treatment of Parkinson's disease. J Neural Transm 1995; 45(suppl): 231-238.
41. Rascol O, Lees AJ, Senard JM, et al. Ropinirole in the treatment of levodopa induced motor fluctuation in patients with Parkinson's disease. Clin Neuropharmacol 1996; 19: 234-245.
42. Boothman BR, Spokes EGS. Pharmacokinetic data for ropinirole. Lancet 1990; 336: 814.
43. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995; 18: 338-347.
44. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advance Parkinson's disease: results of a double-blind, placebo controlled, parallel-group study. Neurology 1997; 49: 162-168.
45. Guttman M and the International Pramipexole-Bromocriptine Study Group. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. Neurology 1997; 49: 1060-1065.
46. Christian Shilling J, Adamus WS, Palluk R. Neuroendrocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans. Clin Pharmacoly and Therapeutics 1992; 51: 541-548.
47. Korczyn M, Brooks DJ, Brunt ER et al. Ropinirole vs. bromocriptine in the treatment of early Parkinson's disease: a 6 month interim report of a 3-year study. Mov Dis 1998; 13: 46-51.
48. Geminiani G, Fetoni V, Genitrini S, Giovannine P, Tamma F, Caraceni T. Cabergoline in Parkinson's disease complicated by motor fluctuations. Mov Dis 1996; 11: 495-500.
49. Carvey PM, Pieri S, Ling ZD. Attenuation of levodopa induced toxicity in mesencephalic cultures by pramipexole. J Neural Trasm 1997; 104: 209-228.
50. Yoshikawa T, Minamiyama Y, Naito Y, Kondo M. Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 1994; 62: 0134-1038.
51. Olanow CW. A rationale for using dopamine agonists as primary symptomatic therapy in Parkinson's disease. In: Olanow CW, Obeso JA eds. Dopamine agonists in early Parkinson's disease. Kent, UK. Wells Medical, 1997; 37-52.
52. Goetz C. Dopaminergic agonists in the treatment of Parkinson' s disease. Neurology 1990; 40: 50-54.
53. Poewe W, Kleedorfer B, Gerstenbrand F. Subcutaneous apomorphine in Parkinson's disease. Lancet 1988; 23: 943.
54. Poewe W, Kleedorfer B, Wagner M, Bosch S, Schelosky L. Continuous apomorphine infusions for fluctuating Parkinson's disease: Long-term follow-up in 18 patients. Adv Neurol 1993; 60: 656-659.
55. Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 1993; 8: 165-170.
56. Kapoor R, Turjanski N, Frankel J, Kleedorfer B, Lees A, Stern G. Intranasal apomorphine: a new treatment in Parkinson's disease (letter). J Neurol Neurosurg Psychiatry 1990; 1: 1015.
57. Van Laar T, Jansen EN, Essink AW, Neef C. Intranasal apomorphine in parkinsonian on-off fluctuations. Arch Neurol 1992; 49: 482-484.
58. Galvez-Jimenez N, Lang AE. Perioperative problems in Parkinson's disease and their management: Apomorphine with rectal domperidone. Can J Neurol Sci 1996; 23: 198-203.
59. Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann Neurol, 1996; 40: 99-107.
60. Parkinson Study Group. Effect of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Eng J Med 1993; 328: 176-183.
61. Schulzer M, Mak E, Calne DB. The antiparkinsonian effiacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol 1992; 32: 795-798.
62. Parkinson Study Group. Impact of deprenyl and tocopherol treatment of Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol, 1996; 39: 29-36.
63. Parkinson Study Group. Impact of deprenyl and tocopherol treatment of Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol, 1996; 39: 37-45.
64. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995; 38: 771-777.
65. Lees AJ, Parkinson's Disease Research Group of the United Kingdom. Comparisonof therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early mild Parkinson's disease. Br Med J 1995; 311: 1602-1607.
66. Parkinson Study Group. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Ann Neurol 1998; 43: 318-325.
67. DaPrada M, Borgulya J, Napolitano A, Zurcher G. Improved therapy of Parkinson's disease with tolcapone, a central and peripheral COMT inhibitor with an S-adenosyl-1-methionine-sparing effect. Clin Neuropharmacol 1994; 17: S26-S37.
68. Davis TL, Roznoski M, Burns RS. Acute effects of COMT inhibition on L-Dopa pharmacokinetics in patients treated with carbidopa and selegiline. Clin Neuropharmacol 1995; 18: 333-337.
69. Limousin P, Pollack P, Pfefen JP, et al. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor in Parkinson's disease. Clin Neuropharmacol 1995; 18: 258-265.
70. Waters CH, Kurth H, Baily P et al. Tolcapone in stable Parkinson's disease: efficacy and safety in long term treatment. Neurology 1997; 49: 665-671.
71. Rajput A, Martin WRW, Sainte-Hillaire MH et al. Tolcapone improves motor function in Parkinsonian patients with the 'wearing off phenomenon: a double-blind placebo controlled multicenter trial. Neurology 1997; 49: 1066-1071.
72. Assal F, Spahr L, Hadengue A et al. Tolcapone and fuminant hepatitis. Lancet 1998; 352: 9132.
73. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa treated Parkinson's disease patients. Annals of Neurology 1997; 42: 747-755.
74. Shoulson I. Protective therapy for Parkinson's disease. In: Marsden CD, Fahn S, eds.Movement Disorders. 3rd Emergency Department. Buttenworth-Heinemann Ltd. 1994: 165-179.
75. Chase TN, Engler TM, Maral Mouradin M. Contributions of dopaminergic and glutaminergic mechanisms to the pathgenisis of motor response complications in PD. Adv Neurology 1996; 69: 497-501.
76. Greenmayre JT, Eller RV, Zhang Z et al. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist in rodent and primate models. Ann Neurol 1994; 35: 655-661.
77. Selby G. Stereotactic surgery for the relief of Parkinson's disease. J Neurol Sci 1967; 5: 315-342.
78. DeLong MR. Primate models of movement disorders of basal ganglia origin. TINS 1990; 13: 281-285.
79. Miller WC, DeLong MR. Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of parkinsonism. In: Carpenter MB, Jayaraman A, editors. The basal ganglia II. New York: Plenum Press, 1987: 15-427.
80. Alexander GE, Crutcher MD, DeLong MR. Basal ganglia-thalamocortical circuits: Parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res 1990; 85: 119-146.
81. Rand RW, Jacques DB, Melbye RW, Copcutt BG, Fisher MR, Levenick MN. Gamma knife thalamotomy and pallidotomy in patients with movement disorders: preliminary results. Stereotact Funct Neurosurg 1993; 61(suppl 1): 65-92.
82. Fox MW, Ahlskog JE, Kelly PJ. Stereotactic ventrolateralis thalamotomy of medically refractory tremor in post-levodopa era Parkinson's disease patients. J Neurosurg 1991; 75: 723-730.
83. Diederich N, Goetz CG, Stebbins GT, Klawans HL, Nittner K, Koulosakis A, et al. Blinded evaluation confirms long-term asymmetric effect of unilateral thalamotomy or subthalamotomy on tremor in Parkinson's disease. Neurology 1992; 42: 1311-1314.
84. Matsumoto K, Shichijo F, Fukami T. Long-term follow-up review of cases of Parkinson's disease after unilateral or bilateral thalamotomy. J Neurosurg 1984; 60: 1033-1044.
85. Page RD. The use of thalamotomy in the treatment of levodopa-induced dyskinesia. Acta Neurochir (Wien) 1992; 114: 77-117.
86. Benabid AL, Pollack P, Gervason C, Hoffman D, Gao DM, Hommel M, et al. Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet 1991; 337: 403-406.
87. Caparros-Lefebvre D, Blond S, Vermersch P, Pecheux N, Guieu J-D, Petit H. Chronic thalamic stimulation improves tremor and levodopa induced dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1993; 56: 268-273.
88. Strafella A, Ashby P, Munz M, Dostrovsky JO, Lozano AM, Lang AE. Inhibition of voluntary activity by thalamic stimulation in humans: Relevance for the control of tremor. Mov Disord 1997; 12: 727-737.
89. Caparros-Lesebvre D, Ruchoux MM, Blond S, Petit H, Percheron G. Long-term thalamic stimulation in Parkinson's disease: postmortem anatomoclinical study. Neurology 1994; 44: 1856-1860.
90. Svennilson E, Torvik A, Lowe R, Leksell L. Treatment of parkinsonism by stereotactic thermo lesions in the pallidal region. A clinical evaluation of 81 cases. Acta Psychiatr Neurol Scand 1960; 35: 358-377.
91. Goetz CG, De Long MR, Penn RD, Bakay RAE. Neurosurgical horizons in Parkinson's disease. Neurology 1993; 43: 1-7.
92. Ceballos-Baumann AO, Obeso JA, Vitek JL, DeLong MR, Bakay R, Linazasoro G, et al. Restoration of thalamocortical activity after posteroventral pallidotomy in Parkinson's disease. Lancet 1994; 344: 314
93. Grafton ST, Waters C, Sutton J, Lew MF, Couldwell W. Pallidotomy increases activity of motor association cortex in Parkinson's disease: A positron emission tomographic study. Ann Neurol 1995; 37: 776-783.
94. Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg 1992; 76: 53-61.
95. Dogali M, Fazzini E, Kolodny E, Eidelberg D, Sterio D, Devinsky O, et al. Stereotactic ventral pallidotomy for Parkinson's disease. Neurology 1995; 45: 753-761.
96. Sutton JP, Couldwell W, Lew MF, Mallory L, Grafton S, DeGiorgio C, et al. Ventroposterior medial pallidotomy in patients with advanced Parkinson's disease. Neurosurgery 1995; 36: 1112-1117.
97. Iacono RP, Shima F, Lonser RR, Kuniyoshi S, Maeda G, Yamada S. The results, indications, and physiology of posteroventral pallidotomy for patients with Parkinson's disease. Neurosurgery 1995; 36: 1118-1127.
98. Baron MS, Vitek JL, Bakay RAE, Green J, Kaneoke Y, Hashimoto T, et al. Treatment of Advanced Parkinson's Disease by Posterior GPi Pallidotomy: 1-Year Results of a Pilot Study. Ann Neurol 1996; 40: 355-366.
99. Johansson F, Malm J, Nordh E, Hariz M. Usefulness of pallidotomy in advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 62: 125-132.
100. Kishore A, Tumbull IM, Snow BJ, De la Fuente-Fernandez R, Schulzer M, Mak E, et al. Efficacy, stability and predictors of outcome of pallidotomy for Parkinson's disease - Six-month follow-up with additional 1-year observations. Brain 1997; 120: 729-737.
101. Kopyov O, Jacques D, Duma C, Buckwalter G, Kopyov A, Lieberman A, et al. Microelectrode-guided posteroventral medial radiofrequency pallidotomy for Parkinson's disease. J Neurosurg 1997; 87: 52-59.
102. Uitti RJ, Wharen RE, Turk MF, Lucas JA, Finton MJ, Graff-Radford NR, et al. Unilateral pallidotomy for Parkinson's disease: Comparison of outcome in younger versus elderly patients. Neurology 1997; 49: 1072-1077.
103. Samuel M, Caputo E, Brooks DJ, Schrag A, Scaravilli T, Branston NM, et al. A study of medial pallidotomy for Parkinson's disease: clinical outcome, MRI location and complications. Brain 1998; 121: 59-75.
104. Ondo WG, Jankovic J, Lai EC, Sankhla C, Khan M, Ben-Arie L, et al. Assessment of motor function after stereotactic pallidotomy. Neurology 1998; 50: 266-270.
105. Shannon KM, Penn RD, Kroin JS, Adler CH, Janko KA, York M, et al. Stereotactic pallidotomy for the treatment of Parkinson's disease - Efficacy and adverse effects at 6 months in 26 patients. Neurology 1998; 50: 434-438.
106. Scott R, Gregory R, Hines N, Carroll C, Hyman N, Papanasstasiou V, et al. Neuropsychological, neurological and functional outcome following pallidotomy for Parkinson's disease - A consecutive series of eight simultaneous bilateral and twelve unilateral procedures. Brain 1998; 121: 659-675.
107. Lozano AM, Lang AE, Galvez-Jimenez N, Miyasaki J, Duff J, Hutchison WD, et al. Effect of GPi pallidotomy on motor function in Parkinson's disease. Lancet 1995; 346: 1383-1387.
108. Lang AE, Lozano AM, Montgomery E, Duff J, Tasker R, Hutchison W. Posteroventral Medial Pallidotomy in Advanced Parkinson's Disease. N Engl J Med 1997; 337: 1036-1042.
109. Giller CA, Dewey RB, Ginsburg MI, Mendelsohn DB, Berk AM. Stereotactic pallidotomy and thalamotomy using individual variations of anatomic landmarks for localization. Neurosurgery 1998; 42: 56-62.
110. Schuurman PR, De Bie RMA, Speelman JD, Bosch DA. Bilateral posteroventral pallidotomy in advanced Parkinson's disease in three patients. Mov Disord 1997; 12: 752-755.
111. Baron MS, Vitek JL, Bakay RAE, Green J, Kaneoke Y, Hashimoto T, et al. Neuropsychological and behavioral changes and weight gain after medial pallidotomy - Reply. Ann Neurol 1997; 41: 835-836.
112. Soukup VM, Ingram F, Schiess MC, Bonnen JG, Nauta HJW, Calverley JR. Cognitive sequelae of unilateral posteroventral pallidotomy. Arch Neurol 1997; 54: 947-950.
113. Perrine K, Dogali M, Fazzini E, Sterio D, Kolodny E, Eidelberg D, et al. Cognitive functioning after pallidotomy for refractory Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 65: 150-154.
114. Trépanier LL, Saint-Cyr JA, Lozano AM, Lang AE. Neuropsychological consequences of posteroventral pallidotomy for the treatment of Parkinson's disease. Neurology 1998; 51: 207-215.
115. Lozano A, Hutchison W, Kiss Z, Tasker R, Davis K, Dostrovsky J. Methods for microelectrode-guided posteroventral pallidotomy. J Neurosurg 1996; 84: 194-202.
116. Siegfried J, Lippitz B. Bilateral chronic electrostimulation of ventroposterolateral pallidum: A new therapeutic approach for alleviating all parkinsonian symptoms. Neurosurgery 1994; 35: 1126-1130.
117. Krack P, Pollak P, Limousin P, Hoffmann D, Xie J, Benazzouz A, et al. Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease. Brain 1998; 121: 451-457.
118. Pahwa R, Wilkinson S, Smith D, Lyons K, Miyawaki E, Koller WC. High-frequency stimulation of the globus pallidus for the treatment of Parkinson's disease. Neurology 1997; 49: 249-253.
119. Kumar R, Lozano AM, Montgomery E, Lang AE. Pallidotomy and deep brain stimulation of the pallidum and subthalamic nucleus in advanced Parkinson's disease. Mov Disord 1998; 13: 73-82.
120. Galvez-Jimenez N, Lang AE, Lozano A, Tasker R, Duff J, Hutchinson WD, et al. Deep brain stimulation in Parkinson's disease: new methods of tailoring functional surgery to patient needs and response. Neurology 1996; 46: A402
121. Krack P, Pollak P, Limousin P, Hoffmann D, Benazzouz A, Benabid AL. Inhibition of levodopa effects by internal pallidal stimulation. Mov Disord 1998; 13: 648-652.
122. Krack P, Pollak P, Limousin P, Hoffman D, Benazzouz A, Le Bas JF, et al. Opposite motor effects of pallidal stimulation in Parkinson's disease. Ann Neurol 1998; 43: 180-192.
123. Bejjani B, Damier P, Arnulf I, Bonnet AM, Vidailhet M, Dormont D, et al. Pallidal stimulation for Parkinson's disease - Two targets? Neurology 1997; 49: 1564-1569.
124. Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990; 249: 1436-1438.
125. Sellai F, Hirsch E, Lisovoski F, Mutschler V, Collard M, Marescaux C. Contralateral disappearance of parkinsonian signs after subthalamic hematoma. Neurology 1992; 42: 255-256.
126. Gill SS, Heywood P. Bilateral dorsolateral subthalamotomy for advanced Parkinson's disease. Lancet 1997; 350: 1224-1224.
127. Limousin P, Pollak P, Benazzouz A, Hoffmann D, Le Bas J-F, Broussolle E, et al. Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 1995; 345: 91-95.
128. Limousin P, Pollak P, Benazzouz A, Hoffmann D, Broussolle E, Perret JE, et al. Bilateral subthalamic nucleus stimulation for severe Parkinson's disease. Mov Disord 1995; 10: 672-674.
129. Kumar R, Lozano AM, Kim YJ, Hutchison WD SE, Halket E, Lang AE. Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced PD. Neurology 1998; 51: 850-855.
130. Krack P, Pollak P, Limousin P, Benazzouz A, Benabid AL. Stimulation of subthalamic nucleus alleviates tremor in Parkinson's disease. Lancet 1997; 350: 1675-1675.
131. Krack P, Limousin P, Benabid AL, Pollak P. Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson's disease. Lancet 1997; 350: 1676-1676.
132. Madrazo I, Drucker-Colin R, Diaz V, Martinez-Mata J, Torres C, Becerril JJ. Open Microsurgical Autograft of Adrenal Medulla to the Right Caudate Nucleus in Two Patients with Intractable Parkinson's Disease. N Engl J Med 1987; 316: 831-873.
133. Goetz GC, Olanow WC, Koller W. Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease. N Engl J Med 1989; 320: 337-341.
134. Ahlskog JE, Kelly PJ, van Heerden JA, Stoddard SL, Tyce GM, Windebank AJ, et al. Adrenal Medullary Transplantation Into the Brain for Treatment of Parkinson's Disease: Clinical OUtcome and Neurochemical Studies. Mayo Clin Proc 1990; 65: 305-328.
135. Allen GS, Bums S, Tulipan NB, Parker RA. Adrenal Medullary Transplantation to the Caudate Nucleus in Parkinson's Disease. Arch Neurol 1989; 46: 487-491.
136. Diamond SG, Markham CH, Rand RW, Becker DP, Treciokas LJ. Four-year follow-up of adrenal-to-brain transplants in Parkinson's disease. Arch Neurol 1994; 51: 559-563.
137. Olanow CW, Koller W, Goetz CG, Stebbins GT, Cahill DW, Gauger LL, et al. Autologous Transplantation of Adrenal Medulla in Parkinson's Disease. Arch Neurol 1990; 47: 1286-1289.
138. Watts RL, Freeman A, Goetz C, Graham S, Takers GO, Bakay AE, et al. Autologous Intrastriatal Adrenal Medulla/Nerve Cografts in Parkinson's Disease (PD): Early Results. Neurology 1993; 43: A222
139. Widner H, Tetrud J, Rehncrona S, Snow B, Brundin P, Gustavii B, et al. Bilateral Fetal Mesencephalic Grafting in Two Patients with Parkinsonism Induced by 1-methyl-4-Phenyl-a,2,3,6-Tetrahydropyridine (MPTP). N Engl J Med 1992; 327: 1556-1563.
140. Lindvall O, Widner H, Rehncrona S, Brudin P, Odin P, gustavii J, et al. Transplantation of Fetal Dopamine Neurons in Parkinson's Disease: One-hear Clinical and Neurophysiological Observations in Two Patients with Putaminal Implants. Arch Neurol 1992; 31: 155-173.
141. Spencer DD, Robbins RJ, Naftolin F, Marek KL, Vollmer T, Leranth C, et al. Unilateral Transplantation of Human Fetal Mesencephalic Tissue into the Caudate Nucleus of Patients with Parkinson's Disease. N Engl J Med 1992; 327: 1541-1548.
142. Freed CR, Breeze RE, Rosenberg NL, Schneck SA, Kriek E, Qi J-X, et al. Survival of Implanted Fetal Dopamine Cells and Neurologic Improvement 12 to 46 months after Transplantation for Parkinson's Disease. N Engl J Med 1992; 327: 1549-1555.
143. Freeman TB, Olanow CW, Hauser RA, Nauert GM, Smith DA, Borlongan CV, et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann Neurol 1995; 38: 379-388.
144. Lindvall O, Sawle G, Widner H, Rothwell JC, Björklund A, Brooks D, et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 1994; 35: 172-180.
145. Kordower JH, Freeman TB, Snow BJ, Vingerhoets FJG, Mufson EJ, Sanberg PR, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995; 332: 1118-1124.
146. Dooneief G, Mirabello E, Bell K et al. An estimate of the incidence of depression in idiopathic Parkinson's disease. Archives of Neurology 1992, 49,305-307.
147. Huber SJ, Friedenberg DL, Paulson GW, Shuttleworth EC and Christy JA. The pattern of depressive symptoms varies with progression of Parkinson's disease. J Neurol Neurosurg Psychiatry, 1990; 53; 527-278.
148. Depression in Parkinson's disease. J Psychology 1996; 130(6) 659-667.
149. Brown R, Jahanshahi M. Behavioural Neurology of Movement Disorders. Advances in Neurology 1995; 6: 61-84.
150. Rao SM, Huber SJ & Bornstein RA. Emotional changes with multiple sclerosis and Parkinson's disease. J Consult Clin Psychology 1992: 60: 369-378.
151. Sano M, Stern Y, Williams J, Cote L, Rosenstein R, Mayeux R: Coexisting Dementia and Depression in Parkinson's Disease. Arch Neurol 1989; 46: 1284-1286.
152. Tom T, Cummings JL. Jan 1998. Drugs-Aging; 12(1): 55-74.
153. Richard IH, Kurlan R: A survery of antidepressant use in PD. PSG Neurology 1997 Oct; 49(4): 1168-70.
154. Ritter JL, Alexander B: Retrospective study of selegiline-antidepressant drug interactions and a review of the literature. Ann Clin Psychiatry. 1997 Mar; 9(1): 7-13.
155. Lieberman A. Depression in PD. BNI Quarterly 1997; 13: 27-33.
156. Stein MB, Heuser IJ, Vade TW. Anxiety disorders in patients with PD. Am. J. Psychiatry 1990; 147: 217-220.
157. Lieberman A. Managing the neuropsychiatric symptoms of PD. Neurology. June 1998; 50 Suppl 6: S27-S32.
158. Balldin J, Eden S, Granerus AK, et al. Electroconvulsive therapy in Parkinson's syndrome with "on-off" phenonenon. J Neural Transm 1980; 47: 11-21.
159. Andersen K, Balldin J, Gottfries CG, et al. A double-blind evaluation of electroconvulsive therapy in Parkinson's disease with "on-off phenomenona. Acta Neurol Scand 1987; 76: 191-199.
160. Baruch P, Jouvent R, Vincreau R, Drouillon C, Widlocher D, Agid Y. Improvement of parkinsonism in ECT-treated depressed patients: Parkinson's disease or depression-related extrapyradmidal disorder? World Congress Biological Psychiatry 1985; 452.2(Abstract).
161. Editorial. ECT for Parkinson's disease? Convulsive Ther 1988; 4: 189-191.
162. Abrams R, Swartz CM. Electroconvulsive therapy and prolactin release: Relation to treatment response in melancholia. Convulsive Ther 1985; 1: 38-42.
163. Bolwig TG, Hertz MM, Paulson OB, Spotoft H, Rafaelson OJ. The permeability of the blood brain barrier during electrically induced seizures in man. Eur J Clin Investigation 1977; 7: 87-93.
164. Sandyk R. Mechanisms of action of ECT in Parkinson's disease: possible role of pineal melantonin. Int J Neurosci 1990; 50: 83-94.
165. Saint-Cyr JA, Taylor AE, Lang AE. Neuropsychological and psychiatric side effects in the treatment of Parkinson's disease. Neurology 1993; 43 Suppl.6.S47-S52.
166. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993; 43: 2227-2229.
167. Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry 1982; 139: 494-497.
168. Lloyd KG, Kornykiewicz O. Occurrence and distribution of aromatic acid (L-dopa) decarboxylase in human brain. J Neurochem 1972; 19: 1549-1559.
169. Kalat JW. Biological psychology. 3rd ed. Belmont, California: Wadsworth Publishing Co. 1988.
170. Moskovitz C, Moses H, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 1978; 135: 669-675.
171. Klawans HL. Psychiatric side effects during the treatment of Parkinson's disease. J Neurol Transm Suppl 1988; 27: 117-122.
172. Marsden CD, Fahn S. Problems in Parkinson's disease. In: Marsden CD, Fahn S, eds. Movement Disorders. London: Butterworth Scientific, 1981: 1-7.
173. Friedman JH, Lannon MC. Clozapine in the treatment of psychosis in PD. Neurology 1989; 39: 1219-1221.
174. Pakkenberg H, Pakkenberg B. Clozapine in the treatment of tremor. Acta Neurol Scand 1986; 73: 295-297.
175. Bennett JP, Jr., Landow ER, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology 1993; 43: 1551-1555.
176. Mendis T, Barclay CL, Mohr E. Drug-induced psychosis in Parkinson's disease: a review of management. CNS Drugs 1996; 5: 166-174.
177. Ford B, Lynch T, Greene P. Risperidone in Parkinson's disease. Lancet 1994; 344: 681.
178. Zoldan J, Friedberg G, Goldberg-Stern H, Melamed E. Ondansetron for hallucinosis in advanced Parkinson's disease. Lancet 1993; 341: 562-563.
179. Zoldan J, Friedberg G, Livneh M, Melamed E. Psychosis in advanced Parkinson's disease: treatment with odansetron, a 5-HT3 receptor antagonist. Neurology 1995; 45: 1305-1308.
180. Pars MA, Bastani B. Quetiapine (Seroquel) in the treatment of psychosis in patients with PD. J Neuropsychiatry Clin Neurosci 1998 Spring; 10(2): 216-9.
181. Mohr E, Mendis T, Grimes Jd. Late cognitive changes in Parkinson's disease with an emphasis on dementia. Behavioural Neurology of Movement Disorders. Emergency department. WJ Werner and AE Lang. Advances in Neurology, Vol 65. Raven Press Ltd. New York 1995: 97-113.
182. Levin BE, Katzen HL. Early cognitive changes and non-dementing behavioural abnormalities in Parkinson's disease. Behavioural Neurology of Movement Disorders Emergency department. WJ Weiner and AE Lang. Advances in Neurology Vol 65. Raven Press Ltd. New York 1995: 85-95.
183. Rho JP, Lipson LG. Focus on donezepil: a reversible acethylcholinesterace inhibitor for the treatment of Alzheimer's disease. Formulary 1997; 32: 677-684.
184. Tanner CM, Goetz CG, Klawans HL. Autonomic nervous system in Parkinson's disease. In: Koller WC, ed. Handbook of Parkinson's disease. New York: Marcel Dekker, 1992: 185-215.
185. Suchowersky Q, Furtado S, Rohs G. Beneficial effect of intranasal desmopressin for nocturnal polyuria in patients with Parkinson's disease. Mov Dis 1995; 10: 337-340.
186. Carter JH, Stewart BJ, Archbold PG et al. Living with a person who has Parkinson's disease; the spouse's perspective by stage of disease. Mov Dis 1998; 13: 20-28